← Back to Search

Tyrosine Kinase Inhibitor

Nintedanib + Sildenafil for Idiopathic Pulmonary Fibrosis

Phase 3

Waitlist Available

Research Sponsored by Boehringer Ingelheim

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and week 24

Awards & highlights

Summary

To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.

Eligible Conditions

Idiopathic Pulmonary Fibrosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and week 24

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and week 24

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score at Week 12

Secondary outcome measures

Change From Baseline in Dyspnoea Using UCSD SOBQ at Week 24

Change From Baseline in Dyspnoea Using the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) at Week 12

Change From Baseline in SGRQ Total Score at Week 24

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Nintedanib + placebo matching sildenafilExperimental Treatment2 Interventions

Group II: Nintedanib + SildenafilActive Control2 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Placebo

1995

Completed Phase 3

~2670

Nintedanib

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Boehringer IngelheimLead Sponsor

2,516 Previous Clinical Trials

11,347,072 Total Patients Enrolled

49 Trials studying Idiopathic Pulmonary Fibrosis

45,107 Patients Enrolled for Idiopathic Pulmonary Fibrosis

~30 spots leftby Sep 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.